Barclays PLC Boosts Holdings in Protagonist Therapeutics, Inc.

Dec 21, 2024 · Barclays PLC boosted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 223.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 126,995 shares of the …

6%
OFF

Barclays PLC Boosts Holdings In Protagonist Therapeutics, Inc.

2 weeks from now

marketbeat.com

$5714000
OFF

Barclays PLC Acquires 87,755 Shares Of Protagonist Therapeutics, …

2 weeks from now

Dec 21, 2024 · Barclays PLC’s holdings in Protagonist Therapeutics were worth $5,714,000 as of its most recent filing with the SEC. Other hedge funds have also bought and sold shares of the …

etfdailynews.com

6%
OFF

Barclays PLC Grows Stock Position In Protagonist Therapeutics, Inc ...

2 weeks from now

Barclays PLC boosted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 223.6% in the 3rd quarter, according to its most recent filing with the …

tickerreport.com

6%
OFF

Protagonist Therapeutics (PTGX) News Today - MarketBeat

2 weeks from now

2 days ago · Barclays PLC boosted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 223.6% in the 3rd quarter, according to its most recent …

marketbeat.com

9%
OFF

Barclays PLC Boosts Stock Position In Perspective Therapeutics, Inc ...

2 weeks from now

2 days ago · Barclays PLC lifted its position in Perspective Therapeutics, Inc. (NYSE:CATX – Free Report) by 587.9% in the third quarter, Holdings Channel.com reports. The firm owned …

etfdailynews.com

4%
OFF

Barclays PLC Raises Holdings In Y-mAbs Therapeutics, Inc.

2 weeks from now

15 hours ago · Barclays PLC lifted its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 433.4% during the third quarter, according to its most …

etfdailynews.com

1%
OFF

Barclays PLC Boosts Holdings In Viridian Therapeutics, Inc

2 weeks from now

Dec 25, 2024 · Barclays PLC grew its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 113.1% during the 3rd quarter, according to the company …

marketbeat.com

39%
OFF

PTGX Stock Price - Protagonist Therapeutics Inc Stock ... - StockScan

2 weeks from now

Protagonist Therapeutics Inc stock is traded at $38.96, with a volume of 455.14K. It is down -1.39% in the last 24 hours and down -13.33% over the past month. Protagonist Therapeutics …

stockscan.io

5%
OFF

Barclays PLC Boosts Holdings In Dianthus Therapeutics, Inc

2 weeks from now

Dec 30, 2024 · Barclays PLC raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 390.5% in the 3rd quarter, according to its most recent disclosure with the …

marketbeat.com

5%
OFF

Barclays PLC Boosts Holdings In Dianthus Therapeutics, Inc.

2 weeks from now

Dec 30, 2024 · Barclays PLC raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) by 390.5% in the 3rd quarter, according to its most recent disclosure with the …

defenseworld.net

1%
OFF

Barclays PLC Boosts Stake In Keros Therapeutics, Inc.

2 weeks from now

Dec 24, 2024 · Barclays PLC increased its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) by 140.1% during the third quarter, Holdings Channel.com …

etfdailynews.com

5%
OFF

Barclays PLC Boosts Stake In Astria Therapeutics, Inc.

2 weeks from now

Dec 31, 2024 · Barclays PLC grew its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) by 70.5% during the 3rd quarter, according to the company in …

defenseworld.net

1%
OFF

Barclays PLC Boosts Holdings In Fulcrum Therapeutics, Inc.

2 weeks from now

Jan 4, 2025 · Barclays PLC increased its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) by 367.1% during the 3rd quarter, according to the company …

defenseworld.net

9%
OFF

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired By Barclays …

2 weeks from now

Dec 18, 2024 · Barclays PLC increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 83.9% in the third quarter, according to the company in its …

marketbeat.com

2%
OFF

Barclays PLC Raises Stock Position In Regulus Therapeutics Inc.

2 weeks from now

6 days ago · Barclays PLC lifted its holdings in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS – Free Report) by 285.2% during the 3rd quarter, Holdings Channel …

etfdailynews.com

1%
OFF

Barclays PLC Raises Holdings In Vera Therapeutics, Inc

2 weeks from now

Dec 23, 2024 · Barclays PLC increased its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 94.1% during the 3rd quarter, according to the company in its most recent 13F …

marketbeat.com

FAQs about Barclays PLC Boosts Holdings in Protagonist Therapeutics, Inc. Coupon?

Does Barclays PLC own Regulus Therapeutics Inc?

Barclays PLC lifted its holdings in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS – Free Report) by 285.2% during the 3rd quarter, Holdings Channel reports. The firm owned 84,477 shares of the biopharmaceutical company’s stock after buying an additional 62,549 shares during the period. ...

Does Barclays PLC own Keros Therapeutics?

Barclays PLC’s holdings in Keros Therapeutics were worth $3,484,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Several other hedge funds have also recently made changes to their positions in the company. KBC Group NV increased its holdings in Keros Therapeutics by 52.0% in the 3rd quarter. ...

What is Barclays focusing on?

Barclays details key areas of focus for the UK Government to create the most successful environment for transition finance, critical to global decarbonisation. View thought-leading highlights by our market experts and analysts from across Barclays Investment Bank. ...

Who regulated Barclays Bank UK?

Barclays Bank UK PLC and Barclays Bank PLC are each authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. Barclays Insurance Services Company Limited and Barclays Investment Solutions Limited are each authorised and regulated by the Financial Conduct Authority. ...

What is Barclays Business Prosperity Index?

Barclays has launched the Business Prosperity Index – a new quarterly analysis of business performance and future growth opportunities. Retail continued to recover in October amid widespread promotional activity, boosted by online shopping and the strong performance of clothing and department stores. ...

Are Barclays insurance services regulated?

Barclays Insurance Services Company Limited and Barclays Investment Solutions Limited are each authorised and regulated by the Financial Conduct Authority. Barclays is a British universal bank. Our businesses include consumer banking, as well as a top-tier, global corporate and investment bank. ...